The topical anti-acne preparation clindamycin HCl has low bioavailability (5-8%) because its hydrophilic makes it difficult to penetrate the stratum corneum where Propionibacterium acnes resides. Efforts have been made to increase the bioavailability of clindamycin HCl through development into transethosomes, but clindamycin HCl transethosomes have less than optimal stability (shelf life